Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 20 | 2023 | 511 | 1.720 |
Why?
|
| Health Care Costs | 10 | 2019 | 371 | 1.160 |
Why?
|
| Quality-Adjusted Life Years | 16 | 2021 | 112 | 0.980 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2021 | 32 | 0.870 |
Why?
|
| Rhytidoplasty | 1 | 2022 | 10 | 0.790 |
Why?
|
| Drugs, Generic | 1 | 2021 | 13 | 0.770 |
Why?
|
| Decision Support Techniques | 5 | 2019 | 292 | 0.770 |
Why?
|
| Drug Costs | 1 | 2021 | 60 | 0.740 |
Why?
|
| Wound Healing | 4 | 2019 | 458 | 0.680 |
Why?
|
| Raynaud Disease | 1 | 2018 | 4 | 0.620 |
Why?
|
| Scleroderma, Localized | 1 | 2018 | 6 | 0.620 |
Why?
|
| Skin Ulcer | 1 | 2018 | 33 | 0.610 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 23 | 0.560 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 334 | 0.510 |
Why?
|
| Primary Prevention | 1 | 2017 | 168 | 0.500 |
Why?
|
| Insurance Coverage | 4 | 2023 | 121 | 0.480 |
Why?
|
| Prescription Drugs | 1 | 2015 | 54 | 0.480 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 265 | 0.470 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 606 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1237 | 0.420 |
Why?
|
| Forehead | 2 | 2022 | 13 | 0.410 |
Why?
|
| Models, Economic | 5 | 2019 | 51 | 0.360 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 1604 | 0.330 |
Why?
|
| Fingers | 2 | 2019 | 65 | 0.310 |
Why?
|
| Replantation | 2 | 2019 | 56 | 0.310 |
Why?
|
| Prognosis | 4 | 2019 | 4607 | 0.260 |
Why?
|
| Education, Medical, Continuing | 2 | 2017 | 138 | 0.250 |
Why?
|
| United States | 15 | 2023 | 10886 | 0.250 |
Why?
|
| Humans | 35 | 2023 | 124797 | 0.240 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 632 | 0.230 |
Why?
|
| Insurance, Health | 2 | 2023 | 138 | 0.230 |
Why?
|
| Medicare | 4 | 2016 | 425 | 0.220 |
Why?
|
| Research Design | 2 | 2018 | 690 | 0.210 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 171 | 0.210 |
Why?
|
| Tissue Expansion | 1 | 2022 | 14 | 0.210 |
Why?
|
| Rhinoplasty | 1 | 2023 | 44 | 0.200 |
Why?
|
| Eyebrows | 1 | 2022 | 13 | 0.200 |
Why?
|
| Rejuvenation | 1 | 2022 | 10 | 0.200 |
Why?
|
| Amputation, Traumatic | 2 | 2019 | 10 | 0.200 |
Why?
|
| Skin | 2 | 2022 | 512 | 0.190 |
Why?
|
| Finger Injuries | 2 | 2019 | 20 | 0.190 |
Why?
|
| Cicatrix | 1 | 2022 | 123 | 0.190 |
Why?
|
| Ear, External | 1 | 2021 | 22 | 0.190 |
Why?
|
| Arteries | 2 | 2019 | 219 | 0.180 |
Why?
|
| Vascular Grafting | 2 | 2019 | 46 | 0.180 |
Why?
|
| Surgical Flaps | 1 | 2022 | 204 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2019 | 3435 | 0.180 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2020 | 10 | 0.170 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 6 | 0.170 |
Why?
|
| Orphan Drug Production | 1 | 2020 | 5 | 0.170 |
Why?
|
| Endoscopy | 1 | 2022 | 284 | 0.170 |
Why?
|
| Graft Survival | 2 | 2019 | 532 | 0.170 |
Why?
|
| Surgery, Plastic | 1 | 2021 | 111 | 0.160 |
Why?
|
| Leeching | 1 | 2019 | 1 | 0.160 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 77 | 0.160 |
Why?
|
| Perforator Flap | 1 | 2019 | 9 | 0.160 |
Why?
|
| Clinical Competence | 2 | 2016 | 997 | 0.160 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2020 | 241 | 0.150 |
Why?
|
| Gross Domestic Product | 1 | 2018 | 1 | 0.150 |
Why?
|
| Dermatologic Agents | 1 | 2018 | 33 | 0.150 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2018 | 45 | 0.150 |
Why?
|
| Life Tables | 1 | 2018 | 30 | 0.150 |
Why?
|
| Triterpenes | 1 | 2018 | 21 | 0.150 |
Why?
|
| Upper Extremity | 1 | 2018 | 53 | 0.150 |
Why?
|
| Treatment Outcome | 11 | 2021 | 12342 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1247 | 0.140 |
Why?
|
| Male | 14 | 2023 | 61285 | 0.140 |
Why?
|
| Decision Making | 3 | 2017 | 654 | 0.140 |
Why?
|
| Income | 1 | 2018 | 133 | 0.140 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 113 | 0.140 |
Why?
|
| Nutrition Therapy | 1 | 2017 | 12 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 137 | 0.140 |
Why?
|
| Educational Measurement | 2 | 2016 | 323 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2015 | 1196 | 0.130 |
Why?
|
| Survival Rate | 2 | 2019 | 2035 | 0.130 |
Why?
|
| Societies, Medical | 2 | 2021 | 689 | 0.130 |
Why?
|
| Certification | 1 | 2016 | 67 | 0.130 |
Why?
|
| Developing Countries | 1 | 2018 | 269 | 0.130 |
Why?
|
| Choice Behavior | 2 | 2014 | 131 | 0.130 |
Why?
|
| Female | 13 | 2021 | 66555 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 98 | 0.120 |
Why?
|
| Regeneration | 1 | 2018 | 203 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 354 | 0.120 |
Why?
|
| Health Policy | 2 | 2014 | 212 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2020 | 767 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 435 | 0.120 |
Why?
|
| Nerve Block | 1 | 2015 | 65 | 0.110 |
Why?
|
| Malnutrition | 1 | 2017 | 204 | 0.110 |
Why?
|
| Ischemia | 2 | 2019 | 357 | 0.110 |
Why?
|
| Anesthesiology | 1 | 2015 | 93 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2015 | 193 | 0.110 |
Why?
|
| Global Health | 1 | 2018 | 558 | 0.110 |
Why?
|
| Efficiency | 1 | 2013 | 61 | 0.100 |
Why?
|
| Sympathectomy | 1 | 2012 | 7 | 0.100 |
Why?
|
| Health Care Rationing | 1 | 2013 | 58 | 0.100 |
Why?
|
| Patients | 1 | 2013 | 121 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2013 | 103 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 220 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 284 | 0.090 |
Why?
|
| Lower Extremity | 1 | 2012 | 187 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 515 | 0.090 |
Why?
|
| SEER Program | 3 | 2016 | 202 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2903 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5153 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 872 | 0.080 |
Why?
|
| Aged | 9 | 2020 | 19691 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 607 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 1664 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1425 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 1028 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 1783 | 0.080 |
Why?
|
| Middle Aged | 5 | 2019 | 26717 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 3726 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2014 | 855 | 0.070 |
Why?
|
| Child | 3 | 2022 | 24454 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2019 | 16299 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 848 | 0.070 |
Why?
|
| Logistic Models | 3 | 2019 | 1810 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 578 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 880 | 0.070 |
Why?
|
| Heart Failure | 1 | 2020 | 2302 | 0.070 |
Why?
|
| Registries | 3 | 2018 | 1422 | 0.060 |
Why?
|
| Kidney | 1 | 2012 | 1354 | 0.060 |
Why?
|
| Quality of Life | 1 | 2015 | 1948 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 6521 | 0.060 |
Why?
|
| Hypertension | 1 | 2012 | 1314 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2021 | 638 | 0.050 |
Why?
|
| Gender Identity | 1 | 2023 | 70 | 0.050 |
Why?
|
| Nose | 1 | 2023 | 92 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 644 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 6309 | 0.050 |
Why?
|
| Face | 1 | 2023 | 180 | 0.050 |
Why?
|
| Markov Chains | 2 | 2012 | 84 | 0.050 |
Why?
|
| Esthetics | 1 | 2021 | 37 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2021 | 116 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1351 | 0.050 |
Why?
|
| Epoetin Alfa | 1 | 2020 | 10 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 269 | 0.040 |
Why?
|
| Publishing | 1 | 2021 | 109 | 0.040 |
Why?
|
| Comorbidity | 2 | 2015 | 1531 | 0.040 |
Why?
|
| Suture Techniques | 1 | 2021 | 198 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2021 | 384 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 188 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2014 | 4783 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2019 | 18 | 0.040 |
Why?
|
| Crush Injuries | 1 | 2019 | 5 | 0.040 |
Why?
|
| Degloving Injuries | 1 | 2019 | 3 | 0.040 |
Why?
|
| Hyperemia | 1 | 2019 | 27 | 0.040 |
Why?
|
| Neoplasms | 1 | 2013 | 2788 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 2817 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 107 | 0.040 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 68 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2018 | 25 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2018 | 25 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 141 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 342 | 0.040 |
Why?
|
| Streptokinase | 1 | 2017 | 20 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2880 | 0.030 |
Why?
|
| American Medical Association | 1 | 2016 | 7 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 443 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2018 | 193 | 0.030 |
Why?
|
| Specialty Boards | 1 | 2016 | 19 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2019 | 308 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 111 | 0.030 |
Why?
|
| Adult | 4 | 2019 | 29472 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2016 | 53 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 17 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2017 | 179 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 199 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 248 | 0.030 |
Why?
|
| Decision Making, Organizational | 1 | 2015 | 4 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 371 | 0.030 |
Why?
|
| Economics, Medical | 1 | 2015 | 7 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2019 | 590 | 0.030 |
Why?
|
| Comprehension | 1 | 2015 | 75 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 298 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2021 | 14050 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1017 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 274 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 498 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 96 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 213 | 0.030 |
Why?
|
| Video Recording | 1 | 2015 | 183 | 0.030 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2014 | 101 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 1309 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2014 | 202 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 807 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 2410 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1108 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1252 | 0.020 |
Why?
|
| Learning | 1 | 2015 | 363 | 0.020 |
Why?
|
| Psychometrics | 1 | 2015 | 676 | 0.020 |
Why?
|
| Catheterization | 1 | 2012 | 236 | 0.020 |
Why?
|
| Patient Participation | 1 | 2013 | 221 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 757 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 1180 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 444 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 873 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 426 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 1022 | 0.020 |
Why?
|
| Communication | 1 | 2013 | 517 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1265 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1616 | 0.020 |
Why?
|
| Animals | 2 | 2019 | 34186 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 8987 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2015 | 1177 | 0.010 |
Why?
|
| Endovascular Procedures | 1 | 2012 | 745 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 12483 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 17748 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 19329 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 1943 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 10272 | 0.010 |
Why?
|